Astat (lanoconazole) / Maruho - LARVOL DELTA

Cooperative inhibition in cytochrome P450 between a substrate and an apparent non-competitive inhibitor. (PubMed, J Biol Chem) - "We performed biochemical and structural analyses of CYP105A1 using the imidazole-containing inhibitors ketoconazole, lanoconazole, and miconazole. Quantum mechanical calculations indicate that Cl-π and electrostatic interactions between diclofenac and lanoconazole, and electrostatic interactions between diclofenac and positively charged arginine residues, stabilize formation of the ESI complex. Based on these results, we propose a mechanism for cooperative inhibition between a substrate and an apparent non-competitive inhibitor."

Journal

First Confirmed Description of Acremonium egyptiacum from Greece and Molecular Identification of Acremonium and Acremonium-like Clinical Isolates. (PubMed, J Fungi (Basel)) - "Flutrimazole, lanoconazole, and luliconazole presented the lower minimum inhibitory concentration (MIC) values against A. egyptiacum, with a geometric mean (GM) MIC of 2.50, 1.92, and 1.57 μg/mL, respectively. Amphotericin B, itraconazole, posaconazole, voriconazole, terbinafine, amorolfine, and griseofulvin MICs were overall high (GM 12.79-29.49 μg/mL)...Antifungal susceptibility of the three different A. egyptiacum genotypes was homogeneous. Overall, the high MICs recorded for all systemically administered drugs, and for some topical antifungals against the tested A. egyptiacum and other acremonium-like clinical isolates, justify the routine susceptibility testing of clinical isolates."

Journal • Brain Cancer • CNS Tumor • Infectious Disease • Oncology • Solid Tumor • Transplantation

Case of tinea corporis caused by a terbinafine-sensitive Trichophyton indotineae strain in a Vietnamese worker in Japan. (PubMed, J Dermatol) - "The lesions were refractory to treatment with topical luliconazole (LLCZ) cream for 4 weeks but subsided with oral itraconazole (ITCZ) 100 mg/day for 4 weeks in combination with topical lanoconazole (LCZ) cream. The reason for recalcitrance in this case, despite the isolate's sensitivity to antimycotics, was unclear. Possible factors include insufficient use of the antimycotics, incomplete removal of abundantly produced conidia from the lesions, the patient's environment, and a language gap between the patient and physician hindering communication."

Journal • Dermatology

Tepidibacillus marianensis sp. nov., a novel heterotrophic iron-reducing bacterium isolated from Mariana Trench sediment. (PubMed, Int J Syst Evol Microbiol) - "Using pyruvate as an electron donor, it was capable of reducing KMnO4, MnO2, As(V), NaNO3, NaNO2, Na2SO4, Na2S2O3, and K2Cr2O7. Based on phenotypic, genotypic, and phylogenetic evidence, strain LSZ-M11000T is proposed to be a novel strain of the genus Tepidibacillus, for which the name Tepdibacillus marianensis is proposed. The type strain is LSZ-M11000T (=CCAM 1008T=JCM 39431T)."

Journal

High Diversity of Fusarium Species in Onychomycosis: Clinical Presentations, Molecular Identification, and Antifungal Susceptibility. (PubMed, J Fungi (Basel)) - "The results of drug susceptibility testing showed high variation among species complexes, and efinaconazole, lanoconazole, and luliconazole showed excellent in vitro activity for the most part. Fusarium onychomycosis has clinical and pathological features distinct from those of dermatophyte onychomycosis. Thus, careful diagnosis and proper pathogen identification are essential in the management of NDM onychomycosis caused by Fusarium sp."

Journal • Infectious Disease

In vitro antifungal susceptibility profile of Iranian Fusarium isolates: Emphasizing on the potent inhibitory effect of efinaconazole compared to other drugs. (PubMed, Mycoses) - "Efinaconazole, a novel triazole, may be a promising candidate for the treatment of superficial Fusarium infections. Furthermore, the development of systemic formulations of these drugs as well as further in vitro and in vivo investigations could aid in the treatment of systemic fusariosis."

Journal • Preclinical • Infectious Disease

Pharmacokinetics of lanoconazole in human skin after repeated topical application. (PubMed, J Dermatol) - "The obtained data were used to evaluate lanoconazole pharmacokinetics in the stratum corneum. The amount of lanoconazole in the stratum corneum after once daily repeated administration reached a steady state on day 3, and it was eliminated from the stratum corneum with a half-life of approximately 11 h after discontinuing application."

Journal • PK/PD data

Prevalence, genetic diversity and antifungal susceptibility profiles of F. fujikuroi, F. solani, and Fusarium incarnatum-equiseti species complexes from onychomycosis in North of Iran. (PubMed, Mycoses) - "Moreover, the minimum inhibitory concentration (MIC) of luliconazole and lanoconazole was in the range of 0.001-1 μg/mL, with the geometric mean of MICs obtained at 0.0103 and 0.0343 μg/mL against Fusarium species, respectively. These findings can increase researchers' knowledge regarding diversity of species, distribution of onychomycosis, and the choice of a proper treatment."

Journal • Infectious Disease

In Vitro Activity of 23 Antifungal Drugs against 54 Clinical and Environmental Aspergillus oryzae isolates. (PubMed, Mycoses) - "The lowest geometric mean MIC values were found for luliconazole and lanoconazole (0.001 μg/ml), followed by anidulafungin (0.104 μg/ml), posaconazole (0.15 μg/ml), itraconazole (0.37 μg/ml), efinaconazole (0.5 μg/ml), voriconazole (0.51 μg/ml), tavaborole (0.72 μg/ml), and amphotericin B (0.79 μg/ml). In contrast, ketoconazole, terbinafine, econazole, tioconazole, ravuconazole, miconazole, nystatin, clotrimazole, griseofulvin, sertaconazole, natamycin, tolnaftate, and fluconazole had no or low activity. Further studies are required to determine how well this in vitro activity translates into in vivo efficacy."

Clinical • Journal • Preclinical • Pulmonary Disease • Respiratory Diseases

Fusarium Keratitis in Taiwan: Molecular Identification, Antifungal Susceptibilities, and Clinical Features. (PubMed, J Fungi (Basel)) - "Among clinically used antifungal agents, amphotericin B registered the lowest minimal inhibitory concentration (MIC), and the new azoles efinaconazole, lanoconazole and luliconazole, demonstrated even lower MICs against Fusarium species. The MICs of natamycin, voriconazole, chlorhexidine, lanoconazole, and luliconazole were higher for the FSSC than the non-FSSC, but no significant differences were noted in clinical outcomes, including corneal perforation and final visual acuity. In Taiwan, the FSSC was the most common complex in Fusarium keratitis; its MICs for five tested antifungal agents were higher than those of non-FSSC, but the clinical outcomes did not differ significantly."

Journal • Keratitis • Ocular Inflammation • Ophthalmology

Eumycetoma Causative Agents are Inhibited in vitro by Luliconazole, Lanoconazole and Ravuconazole. (PubMed, Mycoses) - "The commonly encountered eumycetoma causative agents are inhibited by lanoconazole, luliconazole and ravuconazole. These drugs are promising candidates for further evaluation as potential treatment for eumycetoma."

Journal • Preclinical

A sensitive and rapid bioanalytical method for the quantitative determination of luliconazole in rabbit eye tissues using UPLC-MS/MS assay. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "A selective and sensitive ultrahigh performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS) method was developed for the quantification of LCZ in rabbit ocular tissues, including conjunctiva, cornea, AH, iris, lens, vitreous humor (VH), retinal choroid and sclera, using lanoconazole as internal standard (IS). Luliconazole was stable during the stability studies, including autosampler stability, benchtop stability, freeze/thaw stability and long-term stability. The method was successfully applied to the ocular pharmacokinetic and tissues distribution studies of LCZ in rabbit after topical administration of LCZ ophthalmic drug delivery system."

Journal • Preclinical • Infectious Disease • Keratitis • Ocular Inflammation • Ophthalmology

Comparison of in vitro antifungal activity of novel triazoles with available antifungal agents against dermatophyte species caused tinea pedis. (PubMed, J Mycol Med) - "The novel triazoles showed potent activity against dermatophytes and promising candidates for the treatment of tinea pedis caused by Trichophyton and Epidermophyton species. However, further studies are warranted to determine the clinical implications of these investigations."

Journal • Preclinical • Dermatology

[VIRTUAL] Case of allergic contact dermatitis due to lanoconazole and clobetasol propionate (WAC 2020) - "The password to see abstracts was announced to registrants by email."

Clinical • Dermatitis • Dermatology • Immunology

Anti-inflammatory effect of lanoconazole on 12-O-tetradecanoylphorbol-13-acetate- and 2,4,6-trinitrophenyl chloride-induced skin inflammation in mice. (PubMed, Mycoses) - "The anti-inflammatory effects of LCZ were exerted through the inhibition of inflammatory mediator production. These effects may contribute to the relief of dermatitis symptoms in patients with tinea pedis."

Journal • Preclinical • Dermatitis • Dermatology • Immunology • Infectious Disease

Contact dermatitis caused by efinaconazole and luliconazole. (PubMed, J Nippon Med Sch) - "A patch test with lanoconazole also elicited a positive reaction. However, the chemical formula of ravuconazole, an oral triazole antifungal drug, is similar to that of efinaconazole. Clinicians should carefully consider potential cross-reactivity between these drugs."

Journal • Dermatitis • Dermatology • Immunology

Allergic contact dermatitis due to clobetasol propionate and lanoconazole. (PubMed, Contact Dermatitis) - No abstract available

Journal • Dermatitis • Dermatology • Dermatopathology • Immunology

The Molecular Identification and Antifungal Susceptibilities of Aspergillus Species Causing Otomycosis in Tochigi, Japan. (PubMed, Mycopathologia) - "The Aspergillus strains from this study showed low minimum inhibitory concentrations toward the azole-based drugs efinaconazole, lanoconazole, and luliconazole. Therefore, these topical therapeutic agents may be effective for the treatment of otomycosis."

Journal • Biosimilar • Immunology

A case of cutaneous Paecilomyces formosus infection in an extremely premature infant. (PubMed) - J Infect Chemother - "Neonatologists should consider opportunistic P. formosus infections. This is the first report to describe that micafungin is effective for P. formosus cutaneous infection in extremely premature infants."

Journal • Biosimilar • Immunology

Antifungal drug susceptibility profile of clinically important dermatophytes and determination of point mutations in terbinafine-resistant isolates. (PubMed, Eur J Clin Microbiol Infect Dis) - "Minimum inhibitory concentration range (MIC range) for luliconazole and terbinafine was 0.001-0.008 μg/ml and 0.003-> 32 μg/ml, compared to 0.03-64 μg/ml for griseofulvin, 0.01-16 μg/ml for itraconazole and voriconazole, 0.03-8 μg/ml for ketoconazole, 0.03-32 μg/ml for econazole, 0.03-1 μg/ml for lanoconazole, and 0.01-4 μg/ml for butenafine. Terbinafine resistance was reported for two species, i.e., T. rubrum and T. tonsurans at the total rate of 2% which was due to Leu393Phe substitution in both species. Taken together, our results assist clinicians and prompt the current knowledge about the necessity of antifungal susceptibility testing to select effective strategies for management of clinical cases of dermatophytosis."

Clinical • Journal • Biosimilar

In Vitro Activities of 15 Antifungal Drugs against a Large Collection of Clinical Isolates of Microsporum canis. (PubMed, Mycoses) - "FDA-approved antifungal drugs, that is luliconazole, efinaconazole and lanoconazole, showed the highest antifungal activity and should be promising candidates for the treatment of dermatophytosis caused by M canis. However, their therapeutic effectiveness remains to be determined in clinical settings."

Journal

High prevalence of itraconazole resistance among Candida parapsilosis isolated from Iran. (PubMed, Curr Med Mycol) - "For the purpose of the study, the isolates were subjected to antifungal susceptibility testing against fluconazole (FLZ), itraconazole (ITZ), voriconazole (VRZ), and two new azole drugs, namely luliconazole (LUZU) and lanoconazole (LZN)...This may have been associated with the long-term ITZ prophylaxis/therapy in patients infected with candidiasis. Hence, the adoption of an appropriate antifungal agent is a crucial step for starting the treatment."

Journal

Molecular Cytogenetics Identification of a Wheat-Leymus mollis Double Disomic Addition Line with Stripe Rust Resistance. (PubMed, Genome) - "Evaluation of the agronomic traits revealed that M11003-4-4-1-1 was resistant to stripe rust at the adult stage, while the plant height was reduced and the 1000-grain weight was increased significantly. Therefore, the new line M11003-4-4-1-1 could be exploited as an important bridge material in chromosome engineering and wheat breeding."

Journal

In Vitro Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators Against Dermatophyte Isolates. (PubMed, Antimicrob Agents Chemother) - "The geometric mean MICs were the lowest for luliconazole (0.0005 μg/mL), followed by lanoconazole (0.002 μg/mL), efinaconazole (0.007 μg/mL), terbinafine (0.011 μg/mL), itraconazole (0.095 μg/mL) and fluconazole (12.77 μg/mL). It appears that efinaconazole, lanoconazole and luliconazole are promising candidates for the treatment of dermatophytosis due toand."

Journal • Preclinical

Potent Activity of Luliconazole, Lanoconazole and Eight Comparators against Molecularly Characterizedspecies. (PubMed, Antimicrob Agents Chemother) - "Luliconazole and lanoconazole demonstrated very low GM MIC values of 0.005 μg/ml and 0.013 μg/ml, respectively, in comparison with 0.51 μg/ml for micafungin, 0.85 μg/ml for efinaconazole, 1.12 μg/ml for natamycin, 1.18 μg/ml for anidulafungin, 1.31 μg/ml for voriconazole, 1.35 μg/ml for caspofungin, 1.9 μg/ml for amphotericin B and 4.08 μg/ml for itraconazole. Results show that these drugs are potential candidates for (topical) treatment of skin and nail infections due tospecies."

Journal